



1644.
P#12
PATENT
Attorney Docket No. INL-054DV
(4643/107)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Dahlbäck et al.
SERIAL NO.: 10/037,296 GROUP NO.: 1644
FILING DATE: December 21, 2001 EXAMINER: Not yet assigned.
TITLE: METHODS AND REAGENTS FOR DETERMINING PROTEIN S

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on this 10th day of December, 2002.


Shayna Fischer

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith are:

1. Transmittal Form (1 page);
2. Information Disclosure Statement (2 pages);
3. Form PTO-1449 (13 pages);
4. References Labeled A1 – A44, B1 – B16 and C1-C156; and
5. A return receipt postcard.

RECEIVED

DEC 20 2002

TECH CENTER 1600/2900



TRANSMITTAL FORM

Application Serial Number	10/037,296
Filing Date	December 21, 2001
First Named Inventor	Dahlbäck
Group Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket No.	INL-054DV
Patent No.	Not applicable
Issue Date	Not applicable

TECH CENTER 1600/2900
DEC 20 2002

RECEIVED

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Brief (in triplicate)
<input type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal	<input type="checkbox"/> Status Inquiry
<input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 (13 pgs.) <input checked="" type="checkbox"/> Copies of IDS Citations (A1-A44, B1-B16 and C1-C156)	<input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	<input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8
	<input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
	<input type="checkbox"/> CD(s) for large table or computer program	
	<input type="checkbox"/> Amendment After Allowance	
	<input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Date: December 10, 2002
Reg. No. 43,153
Tel. No.: (617) 310-8168
Fax No.: (617) 248-7100
Diana M. Steel
Attorney for the Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110



PATENT
Attorney Docket No. INL-054DV
(4643/107)

RECEIVED
DEC 20 2002
TECH CENTER 1600/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Dahlbäck and Linse
SERIAL NO.: 10/037,296 GROUP NO.: 1644
FILING DATE: December 21, 2001 EXAMINER: Not Yet Assigned
TITLE: METHODS AND REAGENTS FOR DETERMINING PROTEIN S

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

RECEIVED
DEC 20 2002
TECH CENTER 1600/2900

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT


As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: December 10, 2002
Reg. No. 43,153

Tel. No.: (617) 310-8168
Fax No.: (617) 248-7100


Diana M. Steel
Attorney for Applicants
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644

RECEIVED
DEC 20 2002
TECH CENTER 160012990

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	4,622,389	11/11/86	Nagasawa <i>et al.</i>	530	331	05/09/85
	A2	4,692,406	09/08/87	Becker <i>et al.</i>	435	13	08/20/84
	A3	4,755,461	07/05/88	Lawson <i>et al.</i>	435	13	04/17/86
	A4	4,849,403	07/18/89	Stocker <i>et al.</i>	514	2	05/09/86
	A5	5,001,069	03/19/91	Bartl <i>et al.</i>	436	86	10/04/88
	A6	5,051,357	09/24/91	Hassouna	435	13	08/21/89
	A7	5,059,525	10/22/91	Bartl <i>et al.</i>	435	13	05/29/90
	A8	5,147,805	09/15/92	Preda <i>et al.</i>	436	86	06/29/90
	A9	5,169,786	12/08/92	Carroll <i>et al.</i>	436	69	12/19/89
	A10	5,187,067	02/16/93	Koike <i>et al.</i>	435	7.9	03/14/91
	A11	5,200,322	04/06/93	Matsumoto	435	13	02/28/91
	A12	5,223,427	06/29/93	Edgington <i>et al.</i>	435	240.27	03/09/88
	A13	5,254,350	10/19/93	Barrow <i>et al.</i>	424	570	07/22/91
	A14	5,270,451	12/14/93	Hawkins <i>et al.</i>	530	381	08/06/92
	A15	5,308,756	05/03/94	van de Waart <i>et al.</i>	435	13	11/20/91
	A16	5,314,695	05/24/94	Brown	424	450	10/29/91
	A17	5,358,853	10/25/94	Butler <i>et al.</i>	435	13	08/03/92
	A18	5,374,617	12/20/94	Morrissey <i>et al.</i>	514	8	05/13/92
	A19	5,391,380	02/21/95	Barrow <i>et al.</i>	424	570	05/14/93
	A20	5,405,946	04/11/95	Griffin <i>et al.</i>	530	380	12/02/92
	A21	5,418,141	05/23/95	Zweig <i>et al.</i>	435	13	05/06/94
	A22	5,426,031	06/20/95	Hawkins <i>et al.</i>	435	13	05/25/93
	A23	5,439,802	08/08/95	Rosén	435	13	01/14/92
	A24	5,443,960	08/22/95	Dahlbäck	435	13	05/27/94
	A25	5,472,850	12/05/95	Morrissey	435	13	04/10/91

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644

RECEIVED
DEC 20 2002
TECH CENTER 16001300

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A26	5,502,651	03/26/96	Jackson <i>et al.</i>	364	509	05/02/94
	A27	5,504,064	04/02/96	Morrissey <i>et al.</i>	514	8	02/19/93
	A28	5,504,067	04/02/96	Morrissey <i>et al.</i>	514	8	10/12/94
	A29	5,506,112	04/09/96	Lang <i>et al.</i>	435	13	01/10/92
	A30	5,508,170	04/16/96	Butler <i>et al.</i>	435	13	06/03/94
	A31	5,525,478	06/11/96	Matschiner	435	13	06/07/95
	A32	5,597,700	01/28/97	Konstantinov <i>et al.</i>	435	7.92	04/28/94
	A33	5,643,739	07/01/97	Varadi <i>et al.</i>	435	13	05/01/95
	A34	5,705,395	01/06/98	Griffin <i>et al.</i>	436	69	11/14/94
	A35	5,716,795	02/10/98	Matschiner	435	13	01/03/96
	A36	5,726,028	03/10/98	Kraus	435	13	08/04/95
	A37	5,753,510	05/19/98	Kraus	436	16	11/07/95
	A38	5,766,869	06/16/98	Arkel <i>et al.</i>	435	13	11/27/96
	A39	5,780,255	07/14/98	Preda	435	23	06/09/95
	A40	5,834,223	11/10/98	Griffin <i>et al.</i>	435	13	12/18/97
	A41	5,858,724	01/12/99	Novy, Jr. <i>et al.</i>	435	69.6	07/16/96
	A42	5,874,256	02/23/99	Bertina <i>et al.</i>	435	69.6	02/21/97
	A43	6,083,757	07/04/00	Griffin <i>et al.</i>	436	69	11/10/98
	A44	6,203,816B1	03/20/01	Brown	424	450	04/24/95

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	0 229 234 A1	07/22/87	EP			10/16/86	English	No
	B2	0 271 810 A2	06/22/88	EP			12/08/87	No	Yes

EXAMINER

DATE CONSIDERED

01 F E JC/16
DEC 19 2002
PATENT & TRADEMARK

FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644

RECEIVED
DEC 20 2002
TECH CENTER 16012000

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B3	0 286 323 B1	12/15/93	EP			03/31/88	No	Yes
	B4	0 434 377 B1	08/23/95	EP			12/18/90	No	Yes
	B5	88/07543	10/06/88	PCT			03/29/88	No	Yes
	B6	90/11368	10/04/90	PCT			03/19/90	No	Yes
	B7	91/01382	02/07/91	PCT			07/04/90	No	Yes
	B8	91/01383	02/07/91	PCT			07/5/90	No	Yes
	B9	91/02812	03/07/91	PCT			08/06/90	No	Yes
	B10	92/08479	05/29/92	PCT			11/04/91	No	Yes
	B11	93/01209	01/21/93	PCT			07/02/92	No	Yes
	B12	93/07492	04/15/93	PCT			09/25/92	No	Yes
	B13	93/10261	05/27/93	PCT			05/13/92	No	Yes
	B14	93/13211	07/08/93	PCT			12/29/92	No	Yes
	B15	93/23074	11/25/93	PCT			05/12/93	No	Yes
	B16	95/21938	08/17/95	PCT			02/14/95	No	Yes

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C1	Amer <i>et al.</i> "Impairment of the Protein C Anticoagulant Pathway in a Patient with Systemic Lupus Erythematosus, Anticardiolipin Antibodies and Thrombosis," <u>Thrombosis Research</u> , 57:247-258 (1990).
	C2	Amiral <i>et al.</i> "New Direct Assay of Free Protein S Antigen Using Two Distinct Monoclonal Antibodies Specific for the Free Form," <u>Blood Coag. Fibrin.</u> , 5:179-186 (1994).
	C3	"Antigen-Antibody Crossed Electrophoresis," <u>Analytical Biochemistry</u> , 10(2):358-361 (1965).
	C4	Andrews <i>et al.</i> "Conservation of Tissue Factor Primary Sequence Among Three Mammalian Species," <u>Gene</u> , 98:265-269 (1991).
	C5	Bader <i>et al.</i> "Multicentric Evaluation of a New PT Reagent Based on Recombinant Human Tissue Factor and Synthetic Phospholipids," <u>Thromb. Haemost.</u> , 71(3):292-299 (1994).

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644

OTHER ART, JOURNAL ARTICLES, ETC.

C6	Baele <i>et al.</i> "Comparison of a Recombinant Thromboplastin with Thrombotest™ for Oral Anticoagulant Control," <u>Haemost.</u> , 26:11-15 (1996).
C7	Bauer "Hypercoaguability-A New Cofactor in the Protein C Anticoagulant Pathway," <u>New England Journal of Medicine</u> , 330:566-567 (1994).
C8	Beauchamp <i>et al.</i> "High Prevalence of a Mutation in the Factor V Gene Within the U.K. Population: Relationship to Activated Protein C Resistance and Familial Thrombosis," <u>British J. of Haemost.</u> , 88:219-222 (1994).
C9	Beck <i>et al.</i> "Protein C: ein Inhibitor der Blutgerinnung," <u>Diagnose & Labor</u> , 38:35-42 (Abstract in English) (1988).
C10	Bertina "Specificity of Protein C and Protein S Assays," <u>Res. Clin. Lab.</u> , 20:127-138 (1990).
C11	Bertina <i>et al.</i> "Mutation in Blood Coagulation Factor V Associated with Resistance to Activated Protein C," <u>Nature</u> , 369:64-67 (1994).
C12	Bertina <i>et al.</i> "Determination of Plasma Protein S - The Protein Cofactor of Activated Protein C," <u>Thrombosis Haemostasis</u> , 53:268-272 (1985).
C13	Blangero <i>et al.</i> "Normal Activated Protein C Response has a Large Genetic Component," <u>Florenzia</u> , PS-920, p. 226 (6/9/97).
C14	Blangero <i>et al.</i> "Genetic Factors Influence Quantitative Variation in Tissue Factor Pathway Inhibitor," <u>Florenzia</u> , PS-1666, p. 409 (1997).
C15	Blombäck <i>et al.</i> "Chromogenic Peptide Substrates in the Laboratory Diagnosis of Clotting Disorders," <u>Haemostasis and Thrombosis</u> , Bloom and Thomas (eds.), 2 nd ed, 967-981 (1987).
C16	Boyer-Neumann <i>et al.</i> "Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency," <u>Thomb. and Haemost.</u> , 70(6):946-950 (1993).
C17	Chromogenix, Coatest APC Resistance Kit instructions, May 1993.
C18	Chromogenix, Coatest APC Resistance Kit Brochure, June 1993.
C19	Comp "Laboratory Evaluation of Protein S Status," <u>Seminars in Thromb. and Haemost.</u> , 16(2):177-181 (1990).
C20	Comp <i>et al.</i> "An Abnormal Plasma Distribution of Protein S Occurs in Functional Protein S Deficiency" <u>Blood</u> , 67(2):504-508 (1986).
C21	Cornillon <i>et al.</i> "Rat Coagulation Factor V Purification and Production of the Monospecific Antiserum," <u>Comp. Biochem. Physiol.</u> , 83B, 2: 397-401 (1986).
C22	"Correlation of the APC Ratio with Free Protein S Antigen and with Protein C Activity" Appendix 5, 3 pages (Publication date not known).
C23	Cripe <i>et al.</i> "Structure of the Gene for Human Coagulation Factor V," <u>Biochemistry</u> , 31: 3777-3785 (1992).

EXAMINER

DATE CONSIDERED

TECH CENTER 1600/2800

DEC 20 2002

RECEIVED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644


RECEIVED
DEC 20 2002
TECH CENTER 1600 2900

OTHER ART, JOURNAL ARTICLES, ETC.

C24	Dahlbäck "Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System" <u>Thromb. Haemost.</u> , 66(1):49-61 (1991).
C25	Dahlbäck <i>et al.</i> "Primary Structure of Bovine Vitamin K-Dependent Protein S" <u>Proc. Natl. Acad. Sci.</u> , 83:4199-4203 (1986).
C26	Dahlbäck <i>et al.</i> "Characterization of Functionally Important Domains in Human Vitamin K-Dependent Protein S Using Monoclonal Antibodies" <u>J. Biol. Chem.</u> , 265(14):8127-8135 (1990).
C27	Dahlbäck, <i>et al.</i> "The Protein C Anticoagulant System" <u>The Molecular Basis of Blood Disease</u> , W.B. Saunders Company, Philadelphia, PA, 599-627 (1994).
C28	Dahlbäck <i>et al.</i> "Resistance to Activated Protein C, the FV:Q ⁵⁰⁶ Allele, and Venous Thrombosis," <u>Ann. Hematol.</u> , 72:166-176 (1996).
C29	Dahlbäck "New Molecular Insights into the Genetics of Thrombophilia. Resistance to Activated Protein C Caused by Arg ⁵⁰⁶ to Gln Mutation in Factor V as a Pathogenic Risk Factor for Venous Thrombosis," <u>Thromb. Haemost.</u> , 74(1):139-148 (1995).
C30	Dahlbäck "Factor V Gene Mutation Causing Inherited Resistance to Activated Protein C as a Basis for Venous Thromboembolism," <u>J. Intern. Med.</u> , 237:221-227 (1995).
C31	Dahlbäck <i>et al.</i> "Inherited Resistance to Activated Protein C is Corrected by Anticoagulant Cofactor Activity Found to be a Property of Factor V," <u>Proc. Natl. Acad. Sci.</u> , 91:1396-1400 (1994).
C32	Dahlbäck "A New Model for Coagulation Factor V Suggesting a Unique Mechanism of Activation," <u>Scand. J. Clin. Lab. Invest.</u> , 48, Suppl.191:47-61 (1988).
C33	Dahlbäck "Factor VIII Defect Associated with Familial Thrombophilia," <u>Thrombosis & Haemostasis</u> , 65, Abstract 39:658 (1991).
C34	Dahlbäck <i>et al.</i> "Familial Thrombophilia Due to a Previously Unrecognized Mechanism Characterized by Poor Anticoagulant Response to Activated Protein C: Prediction of a Cofactor to Activated Protein C," <u>Proc. Natl. Acad. Sci.</u> , 90:1004-1008 (1993).
C35	Dahlbäck "Thrombophilia: The Discovery of Activated Protein C Resistance," <u>Advances in Genetics: Incorporating Molecular Genetic Medicine</u> , Academic Press, (Hall <i>et al.</i> eds.), 135-175 (1995).
C36	Dahlbäck <i>et al.</i> "A Natural Anticoagulant Pathway: Proteins C, S, C4b-Binding Protein and Thrombomodulin," <u>Haemostasis and Thrombosis</u> (Bloom <i>et al.</i> eds.), 3 rd edition, Churchill Livingstone, 671-698 (1994).
C37	Dahlbäck "The Protein C Anticoagulant System: Inherited Defects as Basis for Venous Thrombosis," <u>Thrombosis Research</u> , 77:1-43 (1995).
C38	D'Angelo "7 Prothrombin Time Standardization: The Problem of the Control Plasma," <u>Eur. J. Clin. Chem. Clin. Biochem.</u> , 33(12):1019-1022 (1995).
C39	Denson <i>et al.</i> "Validity of the INR System for Patients with Liver Impairment," <u>Thromb. Haemost.</u> , 73(1):162 (1995).
C40	Deutsche Norm, DIN 58 911 "Kalibrierung von Gerinnungszeit-Meßverfahren," 3 pages (English translation provided) (1988).

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644

TECH CENTER 16012900

DEC 20 2002

RECEIVED

OTHER ART, JOURNAL ARTICLES, ETC.

C41	Deutsche Norm DIN 58 939 "Referenzplasma," 4 pages (English translation provided) (1987).
C42	Diagnostica Stago "STACLOT [®] PROTEIN C Additional Information," 1 page (Publication date unknown).
C43	Diagnostica Stago "STACLOT [®] PROTEIN S Additional Information," 1 page (Publication date unknown).
C44	DiScipio <i>et al.</i> "A Comparison of Human Prothrombin, Factor IX (Christmas Factor), Factor X (Stuart Factor), and Protein S," <u>Biochem.</u> , 16:698-704 (1977).
C45	Duchemin <i>et al.</i> "A New Assay Based on Thrombin Generation Inhibition to Detect Both Protein C and Protein S Deficiencies in Plasma," <u>Thomb. and Haemost.</u> , 71(3):331-338 (1994).
C46	Edson <i>et al.</i> "Laboratory Diagnosis of Inherited Protein S Deficiency," <u>Am. J. Clin. Pathol.</u> , 94(2):176-186 (1990).
C47	Esmon "The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation," <u>J. Biol. Chem.</u> , 264(9):4743-4746 (1989).
C48	Esmon "The Regulation of Natural Anticoagulant Pathways," <u>Science</u> , 235:1348-1352 (1987).
C49	Esmon "Protein C: Biochemistry, Physiology, and Clinical Implications," <u>Blood</u> , 62:1155-1158 (1983).
C50	Exner <i>et al.</i> "A Sensitive Test Demonstrating Lupus Anticoagulant and its Behavioural Patterns," <u>Br. Haematol.</u> , 40:143-151 (1978).
C51	Faioni <i>et al.</i> "Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C is Present in Uremic Plasma," <u>Thrombosis and Haemostasis</u> , 66(4):420-425 (1991).
C52	Faioni <i>et al.</i> "Another Protein S Functional Assay is Sensitive to Resistance to Activated Protein C," <u>Thomb. and Haemost.</u> , 72(4):648 (1994).
C53	Faioni <i>et al.</i> "Resistance to Activated Protein C in Nine Thrombophilic Families: Interference in a Protein S Functional Assay," <u>Thromb. and Haemost.</u> , 70(6):1067-1071 (1993).
C54	Fernández <i>et al.</i> "Identification of Residues 413-433 of Plasma Protein S as Essential for Binding to C4b-binding Protein," <u>J. Biol. Chem.</u> , 268(22):16788-16794 (1993).
C55	Fernández <i>et al.</i> "A Protein S Binding Site on C4b-binding Protein Involves β Chain Residues 31-45," <u>J. Biol. Chem.</u> , 269(4):2535-2540 (1994).
C56	Folsom <i>et al.</i> "Prospective Study of Hemostatic Factors and Incidence of Coronary Heart Disease," <u>Circulation</u> , 96(4):1102-1108 (1997).
C57	Forastiero <i>et al.</i> "Evaluation of Recently Described Tests for Detection of the Lupus Anticoagulant," <u>Thromb. Haemost.</u> , 72(5):728-733 (1994).

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644

DEC 20 2002
10012900

RECEIVED

OTHER ART, JOURNAL ARTICLES, ETC.

C58	Gari <i>et al.</i> "The Influence of Low Protein S Plasma Levels in Young Women, on the Definition of Normal Range," <u>Thromb. Res.</u> , 73(2):149-152 (1994).
C59	Giddings <i>et al.</i> "Chapter 12: Laboratory Support in the Diagnosis of Coagulation Disorders," <u>Clinics in Haematology</u> , 14(2):571-595 (1985).
C60	Griffin <i>et al.</i> "Anticoagulant Protein C Pathway Defective in Majority of Thrombophilic Patients," <u>Blood</u> , 82(7):1989-1993 (1993).
C61	Griffin <i>et al.</i> "Activated Protein C Resistance: Molecular Mechanisms," <u>Thromb. Haemost.</u> , 74(1) 444-448 (1995).
C62	Halbmayer <i>et al.</i> "The Prevalence of Poor Anticoagulant Response to Activated Protein C (APC Resistance) Among Patients Suffering from Stroke or Venous Thrombosis and Among Healthy Subjects," <u>Blood Coag. and Fibrin</u> , 5:51-57 (1994).
C63	Han <i>et al.</i> "A Simple Functional Protein S Assay Using PROTAC [®] ," <u>Clin. Lab. Haemat.</u> , 12:201-208 (1990).
C64	Hardig <i>et al.</i> "The Amino-Terminal Module of the C4b-Binding Protein Beta-Chain Contains the Protein S-Binding Site," <u>J. Biol. Chem.</u> , 271(34):20861-20867 (1996).
C65	Hemker <i>et al.</i> "Proteins Induced by Vitamin K Absence (PIVKAs) Effect of Coumarins on Circulating Clotting Factors," <u>Oral Anticoagulants</u> , Poller and Hirsch, eds., Arnold Press, London, 65-75 (1996).
C66	Henkens <i>et al.</i> "Plasma Levels of Protein S, Protein C, and Factor X: Effects of Sex, Hormonal State and Age," <u>Thromb. Haemost.</u> , 74(5):1271-1275 (1995).
C67	Hochuli <i>et al.</i> "Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent," <u>Bio/Technology</u> , 1321-1325 (1988).
C68	Hoffmann <i>et al.</i> "Comparison of Reagents for Determining the Activated Partial Thromboplastin Time," <u>Thromb. Haemost.</u> , 39:640-645 (1978).
C69	Holmberg <i>et al.</i> "Assessment of Blood Coagulation and General Haemostasis," <u>Haemostasis and Thrombosis</u> (Bloom <i>et al.</i> Ed.), Churchill Livingstone, London, 768-774 (1981).
C70	Hoogendoorn <i>et al.</i> " α_2 -Macroglobulin Binds and Inhibits Activated Protein C," <u>Blood</u> , 78(9):2283-2290 (1991).
C71	Kalafatis <i>et al.</i> "Role of the Membrane in the Inactivation of Factor Va by Activated Protein C," <u>J. Biol. Chem.</u> , 268(36):27246-27257 (1993).
C72	Kalafatis <i>et al.</i> "Proteolytic Events That Regulate Factor V Activity in Whole Plasma from Normal and Activated Protein C (APC)-Resistant Individuals During Clotting: An Insight into the APC-Resistance Assay," <u>Blood</u> , 87(11): 4695-4707 (1996).


EXAMINER

DATE CONSIDERED


RECEIVED

DEC 20 2002

TECH CENTER 1600/2900



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: INL-054DV APPLICANTS: Dahlbäck et al. SERIAL NO.: 10/037,296 FILING DATE: December 21, 2001 GROUP: 1644
OTHER ART, JOURNAL ARTICLES, ETC.		
C73	Kamiya <i>et al.</i> "Inherited Deficiency of Protein S in a Japanese Family with Recurrent Venous Thrombosis: A Study of Three Generations," <u>Blood</u> , 67 (2): 406-410 (1986).	
C74	Kane <i>et al.</i> "Blood Coagulation Factors V and VIII: Structural and Functional Similarities and Their Relationship to Hemorrhagic and Thrombotic Disorders," <u>Blood</u> , 71(3):539-555 (1988).	
C75	Kapur <i>et al.</i> "Factor V Inhibitor in Thrombosis," <u>Am. J. Hemat.</u> , 42:384-388 (1993).	
C76	Katzmann "Isolation of Functional Human Coagulation Factor V by Using a Hybridoma Antibody," <u>Proc. Natl. Acad. Sci.</u> , 78(1):162-166 (1981).	
C77	Kisiel "Human Plasma Protein C: Isolation, Characterization and Mechanism of Activation by Alpha Thrombin," <u>J. Clin. Invest.</u> , 64:761-769 (1979).	
C78	Kisiel <i>et al.</i> "Anticoagulant Properties of Bovine Plasma Protein C Following Activation By Thrombin," <u>Biochem.</u> , 16(26):5824-5830 (1977).	
C79	Kisiel <i>et al.</i> "Proteolytic Activation of Protein C from Bovine Plasma," <u>Biochem.</u> , 15(22):4893-4900 (1976).	
C80	Kitchen <i>et al.</i> "Two Recombinant Tissue Factor Reagents Compared to Conventional Thromboplastins for Determination of International Normalised Ratio: A Thirty-Three-Laboratory Collaborative Study," <u>Thromb. Haemost.</u> , 76(3):372-376 (1996).	
C81	Kluft <i>et al.</i> "Effect of Oral Contraceptives on Haemostasis Variables," <u>Thromb. Haemost.</u> , 78(1):315-326 (1997).	
C82	Kobayashi <i>et al.</i> "Functional Activity of Protein S Determined with Use of Protein C Activated by Venom Activator," <u>Clin. Chem.</u> , 35(8):1644-1648 (1989).	
C83	Köhler <i>et al.</i> "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <u>Nature</u> , 256:495-497 (1975).	
C84	Koepke <i>et al.</i> "Partial Thromboplastin Time-Test Proposed Performance Guidelines," <u>Thrombosis and Haemostasis</u> , 55:143-144 (1986).	
C85	Kolde "Standardization of the Prothrombin Time: Clinical Results with a Recombinant Tissue Factor Reagent," <u>Haematologica</u> , 80 (supp to No. 2):7-13 (1995).	
C86	Koster <i>et al.</i> "Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis -- A Case-Control Study of Plasma Levels and DNA Polymorphisms -- The Leiden Thrombophilia Study (LETS)," <u>Thromb. Haemost.</u> , 71(6):719-722 (1994).	
C87	Koster <i>et al.</i> "Role of Clotting Factor VIII in Effect of von Willebrand Factor on Occurrence of Deep-Vein Thrombosis," <u>The Lancet</u> , 345:152-155 (1995).	
C88	Koster <i>et al.</i> "Venous Thrombosis Due to Poor Anticoagulant Response to Activated Protein C: Leiden Thrombophilia Study," <u>The Lancet</u> , 342:1503-1506 (1993).	
EXAMINER		DATE CONSIDERED





FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644


RECEIVED
DEC 20 2002
TECH CENTER

OTHER ART, JOURNAL ARTICLES, ETC.

C89	Kovacs <i>et al.</i> "Assessment of the Validity of the INR System for Patients with Liver Impairment," <u>Thromb. Haemost.</u> , 71(6):727-730 (1994).
C90	Laudano <i>et al.</i> "Synthetic Peptides Modeled on Fibrin Polymerization Sites," <u>Ann. NY Acad. Sci.</u> 408:315-329 (1983).
C91	Laudano <i>et al.</i> "Studies on Synthetic Peptides that Bind to Fibrinogen and Prevent Fibrin Polymerization. Structural Requirements, Number of Binding Sites, and Species Differences," <u>Biochemistry</u> , 19:1013-1019 (1980).
C92	Laudano <i>et al.</i> "Synthetic Peptide Derivatives that Bind to Fibrinogen and Prevent the Polymerization of Fibrin Monomers," <u>Proc. Natl. Acad. Sci.</u> , 75(7):3085-3089 (1978).
C93	Lindblad <i>et al.</i> "Arterial and Venous Thromboembolism with Fatal Outcome and Resistance to Activated Protein C," <u>The Lancet</u> , 343(8902):917 (1994).
C94	Linse <i>et al.</i> "A Region of Vitamin K-Dependent Protein S That Binds to C4b Binding Protein (C4BP) Identified Using Bacterio-phage Peptide Display Libraries," <u>J. Biol. Chem.</u> 272(23):14658-14665 (1997).
C95	Lottenberg <i>et al.</i> "Assay of Coagulation Proteases Using Peptide Chromogenic and Fluorogenic Substrates," <u>Methods in Enzymology</u> (Colowick <i>et al.</i> Ed.), vol. 8, Protedytic Enzymes Part C (Lorand Ed.), Academic Press, 341-361 (1981).
C96	Lundwall <i>et al.</i> "Isolation and Sequence of the cDNA for Human Protein S, a Regulator of Blood Coagulation," <u>Proc. Natl. Acad. Sci.</u> , 83:6716-6720 (1986).
C97	Maccaferri <i>et al.</i> "Protein S Activity in Patients with Heredofamilial Protein S Deficiency and in Patients with Juvenile Venous Thrombosis. Results of a Functional Method," <u>Thromb. Res.</u> , 64:647-658 (1991).
C98	MacCallum <i>et al.</i> "Clotting Factor VIII and Risk of Deep-Vein Thrombosis," <u>The Lancet</u> , 345:804 (1995).
C99	Majerus "Bad Blood by Mutation," <u>Nature</u> , 369:14-15 (1994).
C100	Malm <i>et al.</i> "Changes In the Plasma Levels of Vitamin K-dependent Proteins C and S of C4b-binding Protein During Pregnancy and Oral Contraception," <u>Br. Hemat.</u> , 68:437-443 (1988).
C101	Marlar <i>et al.</i> "Mechanism of Action of Human Activated Protein C, a Thrombin-Dependent Anticoagulant Enzyme," <u>Blood</u> , 59(5):1067-1072 (1982).
C102	Martinoli <i>et al.</i> "Fast Functional Protein C Assay Using Protac, A Novel Protein C Activator," <u>Thrombosis Research</u> , 43:253-264 (1986).
C103	Marciniak "Coagulation Inhibitor Elicited by Thrombin," <u>Science</u> , 170:452-453 (1970).
C104	McAlpine <i>et al.</i> "A <i>Pst</i> I Polymorphism in the Human Coagulation Factor V (F5) Gene," <u>Nucleic Acids Research</u> , 18(24):7471 (1990).

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644


RECEIVED
DEC 20 2002
TECH CENTER 1600/1200

OTHER ART, JOURNAL ARTICLES, ETC.

C105	Miletich <i>et al.</i> "Absence of Thrombosis in Subjects with Heterozygous Protein C Deficiency," <u>New Eng. J. Med.</u> , 317:991-996 (1987).
C106	Mitchell <i>et al.</i> "A Fatal Thrombotic Disorder Associated with an Acquired Inhibitor of Protein C," <u>New Eng. J. Med.</u> , 317:1638-42 (1987).
C107	Murakami <i>et al.</i> "The Level of Tissue Type-Plasminogen Activator and the Rate of Plasma Clot Lysis In Vitro, <u>Thromb. and Haemost.</u> , 65: Abstract 658 (1991).
C108	Nilsson "Assessment of Blood Coagulation and General Haemostasis," <u>Haemost. Thromb.</u> , Bloom Thomas (eds.), 2 nd ed, 922-932 (1987).
C109	O'Donnell <i>et al.</i> "High Prevalence of Elevated Factor VIII Levels in Patients Referred for Thrombophilia Screening: Role of Increased Synthesis and Relationship to the Acute Phase Reaction," <u>Thromb. Haemost.</u> , 77(5):825-828 (1997).
C110	PCT International Search Report for PCT/SE97/01907, 3 pages, dated 11/3/98.
C111	PCT International Preliminary Examination Report for PCT/SE97/01907, 8 pages, dated 3/18/99.
C112	Pel-Freez Biologicals. "Pel-Freez Molecular Diagnostics, Recombinant Rabbit Tissue Factor," <u>Pel-Freez Biologicals</u> , 1-5 (1997).
C113	Poller <i>et al.</i> "The Activated Partial Thromboplastin Time (APTT)," <u>ECAT Assay Procedures-A Manual of Laboratory Techniques</u> (Jespersen <i>et al.</i> Ed.), Kluwer Academic Publishers, 35-40 (1992).
C114	Poort <i>et al.</i> "A Common Genetic Variation in the 3' - Untranslated Region of the Prothrombin Gene is Associated with Elevated Plasma Prothrombin Levels and an Increase in Venous Thrombosis," <u>Blood</u> , 88(10):3698-3703 (1996).
C115	Pratt <i>et al.</i> "Protein C Inhibitor: Purification and Proteinase Reactivity," <u>Thrombos. Res.</u> 53:595-602 (1989).
C116	Preda <i>et al.</i> "A Prothrombin Time-Based Functional Assay of Protein S," <u>Thromb. Res.</u> , 60:19-32 (1990).
C117	Root-Bernstein <i>et al.</i> "Fibrinopeptide A Binds Gly-Pro-Arg-Pro," <u>Proc. Natl. Acad. Sci.</u> , 81:4339-4342 (1984).
C118	Rosén <i>et al.</i> "Multicenter Evaluation of a Kit for Activated Protein C Resistance on Various Coagulation Instruments Using Plasmas from Healthy Individuals," <u>Thromb. Haemost.</u> , 72(2):255-260 (1994).
C119	Rosén <i>et al.</i> "Protein S, an Important Regulatory Protein in Hemostasis," <u>Protein S - Chromogenix Monograph Series</u> , 21 pgs (2000).
C120	Roussi <i>et al.</i> "French Multicentric Evaluation of Recombinant Tissue Factor (Recombiplastin) for Determination of Prothrombin Time," <u>Thromb. Haemst.</u> , 72(5):698-704 (1994).

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: INL-054DV

APPLICANTS: Dahlbäck et al.

SERIAL NO.: 10/037,296

FILING DATE: December 21, 2001

GROUP: 1644


RECEIVED
DEC 20 2002
MECH CENTER 1600/1600

OTHER ART, JOURNAL ARTICLES, ETC.

C121	Salem <i>et al.</i> "Human Coagulation Factor V _a is a Cofactor for the Activation of Protein C," <u>Proc. Nat. Acad. Sci.</u> , 80:1584-1588 (1983).
C122	Seegers <i>et al.</i> "Relationship of 'New' Vitamin K-Dependent Protein C and 'Old' Autoprothrombin II-A," <u>Thromb. Res.</u> , 8:543-552 (1976).
C123	Shen <i>et al.</i> "The Serine Protease Cofactor Factor V is Synthesized by Lymphocytes ¹ ," <u>J. Immun.</u> , 150(7): 2992-3001 (1993).
C124	Shen <i>et al.</i> "Factor V and Protein S as Synergistic Cofactors to Activated Protein C in Degradation of Factor VIIIa," <u>J. Biol. Chem.</u> , 269(29): 18735-18738 (1994).
C125	Simioni <i>et al.</i> "A Protein S Functional Assay Yields Unsatisfactory Results in Patients with Activated Protein C Resistance," <u>Blood Coag. Fibrin.</u> , 6:286-287 (1995).
C126	Solymoss <i>et al.</i> "Kinetics of Inactivation of Membrane-bound Factor Va by Activated Protein C, Protein S Modulates Factor Xa Protection," <u>J. Biol. Chem.</u> , 263(29):14884-14890 (1988).
C127	Spaethe "Hämostase-Physiologie, Pathophysiologie, Diagnostik," 90 (English translation provided) (1984).
C128	Stenflo "Structure and Function of Protein C," <u>Semin. Thromb. Haemost.</u> , 10(27):109-121 (1984).
C129	Stocker <i>et al.</i> "Practical Application of the Protein C Activator Protac from Agkistrodon Contortrix Venom," <u>Folia Haematol.</u> , 115: 260-263 (1988).
C130	Stocker <i>et al.</i> "Protein C Activators in Snake Venoms," <u>Behring Inst. Mitt.</u> , 37-47 (1986).
C131	Sun <i>et al.</i> "Blood Coagulation Factor Va Abnormality Associated with Resistance to Activated Protein C in Venous Thrombophilia," <u>Blood</u> , 83(11): 3120-3125 (1994).
C132	Suzuki <i>et al.</i> "Inactivation of Human Coagulation Factor V by Activated Protein C," <u>J. Biol. Chem.</u> , 258(3):1914-1920 (1983).
C133	Suzuki "Gene Structure of Human Thrombomodulin, a Thrombin Receptor on Endothelium Acting as a Cofactor for Thrombin-Catalyzed Activation of Protein C," <u>Acta Haematol. Jpn.</u> , 51(8):1655-1664 (1988).
C134	Svensson <i>et al.</i> "Resistance to Activated Protein C as a Basis for Venous Thrombosis," <u>N.E. J. Med.</u> , 330:517-522 (1994).
C135	Takahashi <i>et al.</i> "Fast Functional Assay of Protein C in Whole Plasma Using a Snake Venom Activator Evaluation in Patients with Congenital and Acquired Protein C Deficiencies," <u>Clinica Chimica Acta</u> , 175:217-225 (1988).
C136	Thompson <i>et al.</i> "Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris," <u>N.E. J. Med.</u> , 332(10):635-641 (1995).
C137	Tripodi <i>et al.</i> "Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test," <u>Thromb. Haemost.</u> , 67(1):42-45 (1992).

EXAMINER

DATE CONSIDERED



FORM PTO - 1449		ATTORNEY DOCKET NO.: INL-054DV
INFORMATION DISCLOSURE STATEMENT		APPLICANTS: Dahlbäck et al.
		SERIAL NO.: 10/037,296.
		FILING DATE: December 21, 2001
		GROUP: 1644
OTHER ART, JOURNAL ARTICLES, ETC.		
C138	Tuddenham "Thrombophilia: A New Factor Emerges from the Mists," <u>The Lancet</u> , 342:1501-1502 (1993).	
C139	Vasse <i>et al.</i> "Protein C: Rouen, A New Hereditary Protein C Abnormality with Low Anticoagulant But Normal Amidolytic Activities," <u>Thrombosis Research</u> , 56:387-398 (1989).	
C140	Voet <i>et al.</i> "Biochemistry," John Wiley & Sons, Inc. 1086-1095 (1990).	
C141	Voorberg <i>et al.</i> "Association of Idiopathic Venous Thromboembolism with Single Point-Mutation at Arg ⁵⁰⁶ of Factor V," <u>The Lancet</u> , 343:1535-1536 (1994).	
C142	Vukovich <i>et al.</i> "Replacement Therapy for a Homozygous Protein C Deficiency-State Using a Concentrate of Human Protein C and S," <u>Br. J. Haemat.</u> , 70:435-440 (1988).	
C143	Walker <i>et al.</i> "Regulation of Blood Coagulation by the Protein C System," <u>FASEB J.</u> , 6:2561-2567 (1992).	
C144	Walker "Guidelines on The Investigation and Management of Thrombophilia," <u>J. Clin. Pathol.</u> , 43:703-709 (1990).	
C145	Walker <i>et al.</i> "Inactivation of Factor VIII by Activated Protein C and Protein S," <u>Arch. Biochem. Biophys.</u> , 252(1):322-328 (1987).	
C146	Walker "Protein S and the Regulation of Activated Protein C," <u>Semin. Thromb. Haemost.</u> , 10(2):131-138 (1984).	
C147	Walker "Regulation of Bovine Activated Protein C By Protein S: The Role of the Cofactor Protein In Species Specificity," <u>Thromb. Res.</u> , 22:321-327 (1981).	
C148	Walker "Regulation of Activated Protein C by a New Protein," <u>Bio. Chem.</u> , 255(12):5521-5524 (1980).	
C149	Walker <i>et al.</i> "The Inhibition of Blood Coagulation by Activated Protein C Through the Selective Inactivation of Activated Factor V," <u>Biochem. Biophys. Acta</u> , 571:333-342 (1979).	
C150	Wiesel <i>et al.</i> "Screening of Protein S Deficiency Using a Functional Assay in Patients with Venous and Arterial Thrombosis," <u>Thromb. Res.</u> , 58:461-468 (1990).	
C151	Wolf <i>et al.</i> "A New Functional Assay for Human Protein S Activity Using Activated Factor V as Substrate," <u>Thromb. Haemost.</u> , 62(4):1144-1145 (1989).	
C152	Wolf <i>et al.</i> "Clinical Applications of a Direct Assay of Free Protein S Antigen Using Monoclonal Antibodies. A Study of 59 Cases," <u>Blood Coag. Fibrin.</u> , 5:187-192 (1994).	
C153	Wolf <i>et al.</i> "Functional Assay of Protein S in 70 Patients with Congenital and Acquired Disorders," <u>Blood Coag. Fibrin.</u> , 2:705-712 (1991).	
C154	Woodhams <i>et al.</i> "Functional Protein S Assay Shows Improved Correlation with Clinical Symptoms in Hereditary Deficiency," <u>Thromb. Res.</u> , 57:651-657 (1990).	
EXAMINER		DATE CONSIDERED

RECEIVED
DEC 20 2001
TECH CENTER 1600/2900



FORM PTO - 1449		ATTORNEY DOCKET NO.: INL-054DV	
INFORMATION DISCLOSURE STATEMENT		APPLICANTS: Dahlbäck et al.	
		SERIAL NO.: 10/037,296	
		FILING DATE: December 21, 2001	
		GROUP: 1644	
OTHER ART, JOURNAL ARTICLES, ETC.			
	C155	Zöller <i>et al.</i> "Linkage Between Inherited Resistance to Activated Protein C and Factor V Gene Mutation in Venous Thrombosis," <u>The Lancet</u> , 343:1536-1538 (1994).	
	C156	Zöller <i>et al.</i> "Resistance to Activated Protein C as an Additional Genetic Risk Factor in Hereditary Deficiency of Protein S," <u>Blood</u> , 85(12):3518-3523 (1995).	
EXAMINER		DATE CONSIDERED	

RECEIVED

DEC 20 2002

TECH CENTER 1600/2900

2540109_1